THE WOODLANDS, Texas, Feb. 2, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced that they have closed a registered direct offering to sell an aggregate of 2,463,537 shares of common stock for gross proceeds of approximately $11.1 million, before deducting placement agent’s fees and estimated offering expenses. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE Amex:LTS), acted as the exclusive placement agent for the transaction.
